Alderley Analytical

Executive Summary

Alderley Analytical is an independent Contract Research Organisation (CRO) based in Cheshire, UK, providing specialized bioanalytical services for drug development from discovery through clinical trials. Founded in 2008, the company offers precise analysis of small molecules, peptides, oligonucleotides, and large molecules, with a strong emphasis on regulatory compliance under GLP and GCP standards. By operating a single-provider model, Alderley ensures continuity and deep project knowledge for its clients, positioning itself as a reliable partner in the competitive CRO landscape. Despite limited public visibility, the company serves a niche in the growing drug development outsourcing market, particularly within the UK and Europe. As a private, pre-clinical-stage firm, Alderley Analytical has potential for growth through strategic investments, accreditation expansions, and new service offerings. The increasing demand for specialized bioanalytical support in oligonucleotide and large-molecule therapeutics presents a clear opportunity. While the company does not disclose financials or pipeline details, its focus on compliance and client retention suggests a steady business model. Near-term upside may come from expanding its mass spectrometry capabilities or securing multi-year contracts with pharmaceutical sponsors. Overall, Alderley Analytical is a modest but well-positioned CRO in a stable market.

Upcoming Catalysts (preview)

• Q3 2026Expansion of oligonucleotide bioanalysis services70% success
• Q4 2026Major contract win with a top-20 pharma company40% success
• TBDReceipt of CAP/CLIA accreditation for US market entry30% success